What Does a High Ki-67 Index Mean in Your MPNST Report?

A high Ki-67 index on an MPNST pathology report generally means that a larger proportion of the tumor cells show signs of proliferative activity. Ki-67 is a protein that cells express when they are in the active phases of the cell cycle, preparing to divide. When you see a percentage (often called a “labeling index”) next to Ki-67, it estimates the number of tumor cells out of 100 that are active in this way. While a higher percentage is associated with a more aggressive tumor biology ^[1], it is not a direct measurement of exactly how fast the tumor is growing in your body, nor is it proof by itself that the cancer has metastasized (spread to distant parts of the body).

Seeing a high-risk-sounding result on a pathology report can be overwhelming. It is important to know that Ki-67 is just one piece of the puzzle, and your doctors will look at it alongside your full pathology and clinical picture to understand your risk and plan your care ^[2][1].

What a High Ki-67 Does—and Does Not—Mean

In Malignant Peripheral Nerve Sheath Tumors (MPNST), there is no single, universally validated cutoff percentage that defines “high” versus “low” risk ^[1][3]. Instead, researchers view the Ki-67 index as an associated prognostic finding.

• It describes the tumor sample, not your guaranteed outcome: In one specific medical study of 54 MPNST patients, researchers found a group-level association where each 10-point increase in the Ki-67 percentage (for example, from 20% to 30%) was linked to an increased risk of poorer overall survival ^[1]. However, this describes a statistical trend in that specific cohort, not a personal risk calculator for an individual patient.
• Values vary widely: Ki-67 scores in MPNSTs can range anywhere from 5% to 60% or more ^[3].
• It is limited by how it is measured: Pathologists sometimes measure Ki-67 by looking at the most active area of the tumor, known as a hotspot, while other times they take an average across the entire sample ^[4][5]. Because tumors are heterogeneous (not the same throughout) and laboratories use different staining and counting methods, the exact percentage can vary ^[4][5]. You should not directly compare your percentage with a result from another laboratory unless the methods are identical.

How Ki-67 Fits Into Your Treatment Plan

Your care team uses the Ki-67 index as an adjunctive indicator of how aggressive the tumor might be ^[1]. However, Ki-67 alone does not determine your prognosis, and it is never used by itself to choose your treatment or follow-up schedule ^[1][2].

When deciding on treatment, a specialized sarcoma multidisciplinary team will combine your Ki-67 score with much more established clinical factors, including:

• FNCLCC Grade: A scoring system that incorporates how abnormal the cells look (differentiation), how many are actively dividing (mitotic count), and how much dead tissue is present (necrosis) ^[2][6].
• Surgical Margins: Whether the tumor was removed with no cancer cells at the inked edge (a negative or R0 margin), which lowers local recurrence concerns, or if microscopic tumor was found at the edge (a positive margin), which increases the risk of local recurrence ^[7][6].
• Tumor Size, Depth, and Location: Larger tumors or those located deep within the body tend to be more challenging to treat and carry higher risks ^[8][9].
• Metastasis and Staging: Whether imaging scans (like chest CTs or MRIs) show any evidence that the cancer has spread to other parts of the body ^[3].

While completely removing the tumor with surgery remains the primary curative treatment for localized MPNST ^[7], an aggressive tumor profile—based on high grade, large size, positive margins, and potentially supported by a high Ki-67—might prompt discussions about additional therapies. Your team may consider radiation therapy to help control the risk of local recurrence, or in some selective cases, chemotherapy, though routine chemotherapy is not automatically beneficial for every adult patient with MPNST ^[7][10][11].